149 related articles for article (PubMed ID: 27780925)
1. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
[TBL] [Abstract][Full Text] [Related]
2. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
[TBL] [Abstract][Full Text] [Related]
4. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
[TBL] [Abstract][Full Text] [Related]
5. C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.
Zhu Y; Wang C; Zhou Y; Ma N; Zhou J
J Cell Physiol; 2018 Dec; 233(12):9437-9446. PubMed ID: 29968910
[TBL] [Abstract][Full Text] [Related]
6. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
7. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
[TBL] [Abstract][Full Text] [Related]
8. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
[TBL] [Abstract][Full Text] [Related]
9. Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.
Zhou C; Chen Z; Lu X; Wu H; Yang Q; Xu D
Tumour Biol; 2016 Mar; 37(3):3135-44. PubMed ID: 26427664
[TBL] [Abstract][Full Text] [Related]
10. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
11. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
12. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
14. Decyl caffeic acid inhibits the proliferation of colorectal cancer cells in an autophagy-dependent manner in vitro and in vivo.
Chen C; Kuo YH; Lin CC; Chao CY; Pai MH; Chiang EI; Tang FY
PLoS One; 2020; 15(5):e0232832. PubMed ID: 32401800
[TBL] [Abstract][Full Text] [Related]
15. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Hamam R; Ali D; Vishnubalaji R; Alsaaran ZF; Chalisserry EP; Alfayez M; Aldahmash A; Alajez NM
Saudi J Gastroenterol; 2017; 23(1):34-38. PubMed ID: 28139498
[TBL] [Abstract][Full Text] [Related]
17. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
18. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.
Lu XS; Qiao YB; Li Y; Yang B; Chen MB; Xing CG
Oncotarget; 2017 Jan; 8(1):988-998. PubMed ID: 27894091
[TBL] [Abstract][Full Text] [Related]
19. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]